Microvascular Therapeutics Appoints George Kokke to Board of Directors
Veteran family office executive and healthcare investor brings more than 30 years of investment, finance, and board experience.
Tucson, AZ, September 17, 2026 --(PR.com)-- Microvascular Therapeutics, Inc. (MVT), a clinical-stage biotechnology company developing innovative microbubble-based therapies and diagnostic agents, today announced the appointment of George Kokke to its Board of Directors.
Kokke brings more than 30 years of experience in investment management, finance, governance, and private company investing. He previously served as Chief Financial Officer and Chief Investment Officer of a Family Office, where he was responsible for investment and financial activities for the single-family office with more than $1 billion in assets under management.
Kokke has substantial experience investing in biotechnology, medical technology, and healthcare companies and has served as a director or board observer for numerous healthcare companies, including XpandOrtho, Turing Medical, Sensor Therapeutics, T-Curx, and Binx Health. He has also served on limited partner advisory boards for private equity and venture capital funds, including Pureos BioVentures.
“George brings an unusual combination of sophisticated investment experience, financial expertise, healthcare knowledge, and hands-on experience helping emerging companies grow and achieve successful exits,” said Evan Unger, MD, CEO and Executive Chairman of Microvascular Therapeutics. “As MVT advances multiple clinical programs and expands its strategic and financing activities, his perspective will be extremely valuable to our Board.”
“I am very pleased to join the Board of Microvascular Therapeutics,” said Kokke. “MVT has assembled an exciting portfolio of technologies with the potential to address significant unmet needs across diagnostic imaging and therapeutic applications. I look forward to working with Evan and the team as the company advances these programs.”
Kokke received a Bachelor of Science in Business Administration with an emphasis in Finance from the University of Arizona.
About Microvascular Therapeutics
Microvascular Therapeutics, Inc. is a clinical-stage biotechnology company developing next-generation microbubble and phase-shift microbubble technologies for diagnostic and therapeutic applications. The company’s pipeline includes CardiSon™, a next-generation ultrasound enhancing agent; Solv™, a therapeutic phase-shift microbubble platform being developed for microvascular obstruction and thrombotic cardiovascular disease; and NanoBlate™, an ultrasound-activated platform being developed for nonthermal tumor ablation and other therapeutic applications. MVT’s founders and team have extensive experience in the development of ultrasound contrast agents and microbubble therapeutics.
Kokke brings more than 30 years of experience in investment management, finance, governance, and private company investing. He previously served as Chief Financial Officer and Chief Investment Officer of a Family Office, where he was responsible for investment and financial activities for the single-family office with more than $1 billion in assets under management.
Kokke has substantial experience investing in biotechnology, medical technology, and healthcare companies and has served as a director or board observer for numerous healthcare companies, including XpandOrtho, Turing Medical, Sensor Therapeutics, T-Curx, and Binx Health. He has also served on limited partner advisory boards for private equity and venture capital funds, including Pureos BioVentures.
“George brings an unusual combination of sophisticated investment experience, financial expertise, healthcare knowledge, and hands-on experience helping emerging companies grow and achieve successful exits,” said Evan Unger, MD, CEO and Executive Chairman of Microvascular Therapeutics. “As MVT advances multiple clinical programs and expands its strategic and financing activities, his perspective will be extremely valuable to our Board.”
“I am very pleased to join the Board of Microvascular Therapeutics,” said Kokke. “MVT has assembled an exciting portfolio of technologies with the potential to address significant unmet needs across diagnostic imaging and therapeutic applications. I look forward to working with Evan and the team as the company advances these programs.”
Kokke received a Bachelor of Science in Business Administration with an emphasis in Finance from the University of Arizona.
About Microvascular Therapeutics
Microvascular Therapeutics, Inc. is a clinical-stage biotechnology company developing next-generation microbubble and phase-shift microbubble technologies for diagnostic and therapeutic applications. The company’s pipeline includes CardiSon™, a next-generation ultrasound enhancing agent; Solv™, a therapeutic phase-shift microbubble platform being developed for microvascular obstruction and thrombotic cardiovascular disease; and NanoBlate™, an ultrasound-activated platform being developed for nonthermal tumor ablation and other therapeutic applications. MVT’s founders and team have extensive experience in the development of ultrasound contrast agents and microbubble therapeutics.
Contact
Microvascular Therapeutics
Emmanuelle Meuillet
520-730-3264
mvtpharma.com
Emmanuelle Meuillet
520-730-3264
mvtpharma.com
Contact
Categories